Watch the video of subgroup analysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial showed no rebound increase in the risk of ischemic stroke, stroke, transient ischemic attack (TIA), and composite events during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke.